The generation and characterization of transgenic animal models representative of human retinal diseases
37 48 50 53 has made it possible to test the therapeutic prospect of numerous experimental gene therapies.
11 25 36 54 55 56 Several relevant studies have relied heavily on GFP and EGFP to test the expression level and cell specificity of several promoters,
12 13 14 15 16 track the localization of newly delivered cellular therapies,
8 17 18 19 20 21 22 and indicate the targeting ability
3 4 5 6 7 8 9 10 11 and level of viral transduction afforded by viral vectors in the retina.
4 23 24 25 26 27 28 29 Bennett et al.,
28 described the lack of negative effects resulting from long-term GFP expression in the monkey retina. However, others have reported evidence of rejection resulting from lentivirus-mediated expression of GFP in RPE cells.
32 Aside from the prospects of immunologic response to the expression of an exogenous protein, the expression of GFP in the retina poses another challenge. The overlap in emission wavelength of GFP (510 nm) with the absorption wavelength of rhodopsin raises a concern regarding the potential for GFP-induced overactivation of the chromophore. Several studies to date have shown, the devastating effects of rhodopsin overactivation and overexpression in the retina, which in severe cases, led to photoreceptor cell death.
37 38 39 40 41 42 For these reasons, mutations that alter the phototransductory function of rhodopsin may be most vulnerable to GFP-induced damage. Several of these mutations have been linked to retinal diseases, and their prevalence makes rhodopsin transgenic models particularly attractive for the testing and application of gene therapy, which may also make them subject to GFP expression. For this reason, we investigated the effect of retinal EGFP expression on both the normal and, more significantly, the diseased retina of transgenic mice expressing mutations in the opsin gene. The chosen two transgenic models of retinal diseases carry either the G90D or the VPP mutations in rhodopsin have been shown to cause human congential stationary night blindness and RP, respectively. Using both of these mouse models serves to assess the safety of EGFP under conditions of slow, late-onset (G90D) (Naash MI, et al.
IOVS 1996;37:ARVO Abstract 3198),
50 as well as fast, early-onset, light-sensitive patterns of retinal degeneration (VPP).
48